Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 435-443

  Freynhofer, Matthias K ^a   Bruno, Veronika ^a   Jarai, Rudolf ^a   Gruber, Susanne ^a   Höchtl, Thomas ^a   Brozovic, Ivan ^a   Farhan, Serdar ^a   Wojta, Johann ^a   Huber, Kurt ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

ADAMS ADAMTS 13; Atrial fibrillation; Cardioversion; Endothelial dysfunction; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADAM PROTEINS; AGED; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 79952566650     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-09-0615     Document Type: Article

References (43)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
2. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803-808.
3. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82: 1545-1547, A8.
4. Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359-1366. (Pubitemid 23316359)
5. Oltrona L, Broccolino M, Merlini PA, et al. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation 1997 ; 95: 2003-2006. (Pubitemid 27184265)
6. Coll-Vinent B, Monteagudo J, Miro O, et al. Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thromb Res 2006; 117: 235-240. (Pubitemid 41832293)
7. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-1193.
8. Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074.
9. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435. (Pubitemid 13234018)
10. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor- cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103. (Pubitemid 27229791)
11. Uemura T, Kaikita K, Yamabe H, et al. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res 2009; 124: 28-32.
12. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, et al. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999; 84: 147R-151R.
13. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. (Pubitemid 35417773)
14. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147: 121-126. (Pubitemid 38037407)
15. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286-292. (Pubitemid 38250721)
16. Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-2592.
17. Tveit A, Seljeflot I, Grundvold I, et al. Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation. Thromb Res 2008; 121: 447-453. (Pubitemid 351174281)
18. Opolski G, Torbicki A, Kosior D, et al. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol Pol 2003; 59: 1-16. (Pubitemid 36958577)
19. Fatkin D, Kuchar DL, Thorburn CW, et al. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23: 307-316.
20. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23: 961-969. (Pubitemid 24090884)
21. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996; 78: 435-439. (Pubitemid 26277024)
22. Lip GY, Rumley A, Dunn FG, et al. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51: 245-251.
23. Jacob K, Talwar S, Copplestone A, et al. Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin. Int J Cardiol 2004; 95: 83-88. (Pubitemid 38670476)
24. Nikitovic D, Zacharis EA, Manios EG, et al. Plasma Levels of Nitrites/Nitrates in Patients with Chronic Atrial Fibrillation are Increased after Electrical Restoration of Sinus Rhythm. J Interv Card Electrophysiol 2002; 7: 171-176. (Pubitemid 35462314)
25. Katoh H, Shimada T, Inoue S, et al. Reduced high serum hepatocyte growth factor levels after successful cardioversion in patients with atrial fibrillation. Clin Exp Pharmacol Physiol 2004; 31: 145-151. (Pubitemid 38338710)
26. Li-Saw-Hee FL, Blann AD, Gurney D, et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001; 22: 1741-1747. (Pubitemid 32896373)
27. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106. (Pubitemid 38879844)
28. Conway DS, Buggins P, Hughes E, et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-2082. (Pubitemid 38686805)
29. Crawley JT, Lam JK, Rance JB, et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-1093. (Pubitemid 40170879)
30. Heppell RM, Berkin KE, McLenachan JM, et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77: 407-411. (Pubitemid 27278416)
31. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-3145. (Pubitemid 36793082)
32. Matsukawa M, Kaikita K, Soejima K, et al. Serial changes in von Willebrand factor- cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100: 758-763. (Pubitemid 47268262)
33. Crawley JT, Lane DA, Woodward M, et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008; 6: 583-588. (Pubitemid 351418945)
34. Chion CK, Doggen CJ, Crawley JT, et al. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007; 109: 1998-2000. (Pubitemid 46348198)
35. Gombos T, Mako V, Cervenak L, et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102: 573-580.
36. Miura M, Kaikita K, Matsukawa M, et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 2010; 103: 623-629.
37. Conway DS, Buggins P, Hughes E, et al. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004; 94: 508-510. (Pubitemid 39120007)
38. Kaireviciute D, Blann AD, Balakrishnan B, et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010; 104: 122-127.
39. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
40. Bongers TN, Emonts M, de Maat MP, et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost 2010; 103: 1181-1187.
41. Claus RA, Bockmeyer CL, Budde U, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
42. Kourliouros A, Savelieva I, Kiotsekoglou A, et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-252.
43. Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49: 1642-1648. (Pubitemid 46551628)